NASDAQ:NGM

NGM Biopharmaceuticals Competitors

$25.52
-0.55 (-2.11 %)
(As of 04/16/2021 11:04 AM ET)
Add
Compare
Today's Range
$25.52
Now: $25.52
$26.15
50-Day Range
$24.43
MA: $28.11
$31.93
52-Week Range
$14.93
Now: $25.52
$32.12
Volume331 shs
Average Volume294,161 shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97

Competitors

NGM Biopharmaceuticals (NASDAQ:NGM) Vs. RARE, ARWR, GWPH, ASND, TGTX, and IONS

Should you be buying NGM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to NGM Biopharmaceuticals, including Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

NGM Biopharmaceuticals (NASDAQ:NGM) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by company insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for NGM Biopharmaceuticals and Ultragenyx Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
Ultragenyx Pharmaceutical06802.57

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, suggesting a potential upside of 53.26%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, suggesting a potential upside of 20.73%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe NGM Biopharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares NGM Biopharmaceuticals and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Earnings & Valuation

This table compares NGM Biopharmaceuticals and Ultragenyx Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.90$-42,790,000.00($0.85)-30.02
Ultragenyx Pharmaceutical$103.71 million70.15$-402,730,000.00($7.36)-14.76

NGM Biopharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats Ultragenyx Pharmaceutical on 11 of the 15 factors compared between the two stocks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and NGM Biopharmaceuticals (NASDAQ:NGM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Valuation & Earnings

This table compares Arrowhead Pharmaceuticals and NGM Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million79.69$-84,550,000.00($0.84)-80.43
NGM Biopharmaceuticals$103.54 million18.90$-42,790,000.00($0.85)-30.02

NGM Biopharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than NGM Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Arrowhead Pharmaceuticals and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
NGM Biopharmaceuticals-91.64%-29.47%-25.58%

Risk & Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Arrowhead Pharmaceuticals and NGM Biopharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals021002.83
NGM Biopharmaceuticals00523.29

Arrowhead Pharmaceuticals currently has a consensus price target of $85.3077, indicating a potential upside of 26.27%. NGM Biopharmaceuticals has a consensus price target of $39.1111, indicating a potential upside of 53.26%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NGM Biopharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Summary

NGM Biopharmaceuticals beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for NGM Biopharmaceuticals and GW Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
GW Pharmaceuticals010402.29

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, indicating a potential upside of 53.26%. GW Pharmaceuticals has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe NGM Biopharmaceuticals is more favorable than GW Pharmaceuticals.

Valuation & Earnings

This table compares NGM Biopharmaceuticals and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.90$-42,790,000.00($0.85)-30.02
GW Pharmaceuticals$311.33 million22.02$-9,020,000.00($0.24)-911.38

GW Pharmaceuticals has higher revenue and earnings than NGM Biopharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than NGM Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Profitability

This table compares NGM Biopharmaceuticals and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Summary

GW Pharmaceuticals beats NGM Biopharmaceuticals on 9 of the 15 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and NGM Biopharmaceuticals (NASDAQ:NGM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Ascendis Pharma A/S and NGM Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million441.02$-244,180,000.00($5.25)-23.41
NGM Biopharmaceuticals$103.54 million18.90$-42,790,000.00($0.85)-30.02

NGM Biopharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Ascendis Pharma A/S and NGM Biopharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
NGM Biopharmaceuticals00523.29

Ascendis Pharma A/S presently has a consensus target price of $187.6667, indicating a potential upside of 52.69%. NGM Biopharmaceuticals has a consensus target price of $39.1111, indicating a potential upside of 53.26%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NGM Biopharmaceuticals is more favorable than Ascendis Pharma A/S.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Ascendis Pharma A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.

Profitability

This table compares Ascendis Pharma A/S and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
NGM Biopharmaceuticals-91.64%-29.47%-25.58%

Summary

NGM Biopharmaceuticals beats Ascendis Pharma A/S on 12 of the 15 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Institutional and Insider Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 13.2% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares NGM Biopharmaceuticals and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
TG Therapeutics-151,798.69%-223.96%-108.08%

Valuation and Earnings

This table compares NGM Biopharmaceuticals and TG Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.90$-42,790,000.00($0.85)-30.02
TG Therapeutics$150,000.0043,038.06$-172,870,000.00($1.83)-25.09

NGM Biopharmaceuticals has higher revenue and earnings than TG Therapeutics. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for NGM Biopharmaceuticals and TG Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
TG Therapeutics00503.00

NGM Biopharmaceuticals currently has a consensus price target of $39.1111, indicating a potential upside of 53.26%. TG Therapeutics has a consensus price target of $64.00, indicating a potential upside of 39.37%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe NGM Biopharmaceuticals is more favorable than TG Therapeutics.

Volatility and Risk

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Summary

NGM Biopharmaceuticals beats TG Therapeutics on 11 of the 14 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Profitability

This table compares NGM Biopharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
Ionis Pharmaceuticals7.82%6.57%3.39%

Valuation & Earnings

This table compares NGM Biopharmaceuticals and Ionis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.90$-42,790,000.00($0.85)-30.02
Ionis Pharmaceuticals$1.12 billion5.15$303.26 million$2.0819.73

Ionis Pharmaceuticals has higher revenue and earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for NGM Biopharmaceuticals and Ionis Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
Ionis Pharmaceuticals27602.27

NGM Biopharmaceuticals currently has a consensus target price of $39.1111, indicating a potential upside of 53.26%. Ionis Pharmaceuticals has a consensus target price of $57.9091, indicating a potential upside of 41.14%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe NGM Biopharmaceuticals is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats NGM Biopharmaceuticals on 9 of the 15 factors compared between the two stocks.


NGM Biopharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.67-0.8%$7.34 billion$103.71 million-24.75Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.56-0.6%$7.06 billion$87.99 million-80.43
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.73-0.0%$6.86 billion$311.33 million-127.17Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$122.91-1.0%$6.67 billion$14.98 million-14.97Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.92-0.2%$6.44 billion$150,000.00-21.66Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03-1.9%$5.78 billion$1.12 billion85.48
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.52-1.6%$5.77 billion$380.83 million-9.15Analyst Report
Allakos logo
ALLK
Allakos
1.7$105.33-2.7%$5.74 billionN/A-38.44Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95-0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.48-0.7%$5.50 billion$4.84 billion-691.22
Schrödinger logo
SDGR
Schrödinger
1.3$78.18-0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$78.95-0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56-1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13-0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06-1.1%$4.28 billion$204.89 million-36.33
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08-1.4%$4.10 billion$806.43 million-9.50Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.06-2.1%$3.99 billion$1.11 billion24.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28-1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83-2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74-4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99-2.7%$3.60 billionN/A-6.20Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11-1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62-3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$25.40-1.6%$3.43 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14-0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96-1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.07-1.2%$3.34 billion$26.52 million-8.02
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37-0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23-3.6%$3.17 billionN/A-56.33Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.65-0.6%$3.15 billion$1.17 billion-42.72
Arvinas logo
ARVN
Arvinas
1.5$62.57-0.7%$3.08 billion$42.98 million-24.44
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88-5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27-1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22-6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43-1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10-2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18-4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67-0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50-2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28-3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78-4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88-1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76-3.6%$2.48 billion$15 million-17.68Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.93-0.0%$2.47 billion$120.28 million-150.43Analyst Report
Decrease in Short Interest
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50-0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89-4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96-0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33-2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.